ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Alumis Inc. Common Stock (ALMS) stock declined over -1.24%, trading at $4.79 on NASDAQ, down from the previous close of $4.85. The stock opened at $4.70, fluctuating between $4.56 and $4.85 in the recent session.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Employees | 145 |
Beta | 0.72 |
Sales or Revenue | N/A |
5Y Sales Change% | 0% |
Fiscal Year Ends | N/A |
Sector | Healthcare |
Industry | Biotechnology |